DJIA 17,536.96 -152.90 -0.86%
NASDAQ 5,099.31 -28.97 -0.56%
S&P 500 2,090.33 -13.51 -0.64%
market minute promo

546.09 -7.57 (-1.37%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $547.09 -1.19%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $558.47
Previous Close $553.66
Daily Range $547.24 - $561.31
52-Week Range $314.00 - $569.92
Market Cap $56.4B
P/E Ratio 177.46
Dividend (Yield) $0.00 (0.0%)
Volume 284,607
Average Daily Volume 609,756
Current FY EPS $8.31

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

Game Plan For The Week - Cramer's Mad Money (7/31/15)

Will Regeneron (REGN) Earnings Surprise on Eylea Sales? - Analyst Blog

Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?

Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceu

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

See More REGN News...

REGN's Top Competitors

REGN $546.09 (-1.37%)
Current stock: REGN
AMGN $174.33 (-1.28%)
Current stock: AMGN
CELG $130.07 (-0.90%)
Current stock: CELG
GILD $118.92 (0.90%)
Current stock: GILD